ReviewAnnals of vascular diseases2026
Contrast-Induced Nephropathy.
Review in Annals of vascular diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis and treatment of cardiovascular diseases often require the administration of iodinated contrast media. However, it is sometimes difficult to use such contrast media in patients with renal dysfunction because direct mechanisms of tubular cell injury and indirect mechanisms of medullary ischemia, together with the contrast medium, may cause contrast-induced nephropathy (CIN). Although the frequency of developing CIN is said to be lower than previously estimated, once it develops, there is no effective treatment, and it may affect mortality. Therefore, before using a contrast medium, it is necessary to identify the risk factors of CIN in patients-including chronic kidney disease, advanced age, and diabetes mellitus-and understand the risk differences between intravenous and intra-arterial contrast medium administration. If there is any risk, intravenous saline or sodium bicarbonate treatments may be used to prevent CIN onset, and the use of minimum amounts of contrast media, within the corresponding range, may be recommended. (This is a translation of Jpn J Vasc Surg 2024; 33: 143-147.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.